Enzo Biochem ROE 2010-2023 | ENZ
Current and historical return on equity (ROE) values for Enzo Biochem (ENZ) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Enzo Biochem ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2023-01-31 |
$-0.04B |
$0.03B |
-72.16% |
| 2022-10-31 |
$-0.03B |
$0.05B |
-47.79% |
| 2022-07-31 |
$-0.02B |
$0.05B |
-29.03% |
| 2022-04-30 |
$-0.01B |
$0.06B |
-10.65% |
| 2022-01-31 |
$0.00B |
$0.07B |
0.00% |
| 2021-10-31 |
$0.01B |
$0.07B |
7.60% |
| 2021-07-31 |
$0.01B |
$0.07B |
10.98% |
| 2021-04-30 |
$0.00B |
$0.07B |
1.64% |
| 2021-01-31 |
$-0.01B |
$0.06B |
-18.26% |
| 2020-10-31 |
$-0.02B |
$0.06B |
-33.60% |
| 2020-07-31 |
$-0.03B |
$0.06B |
-43.12% |
| 2020-04-30 |
$-0.03B |
$0.06B |
-41.75% |
| 2020-01-31 |
$0.00B |
$0.07B |
1.23% |
| 2019-10-31 |
$0.00B |
$0.08B |
1.24% |
| 2019-07-31 |
$0.00B |
$0.09B |
3.75% |
| 2019-04-30 |
$0.00B |
$0.09B |
2.54% |
| 2019-01-31 |
$-0.02B |
$0.07B |
-29.68% |
| 2018-10-31 |
$-0.02B |
$0.08B |
-19.34% |
| 2018-07-31 |
$-0.01B |
$0.08B |
-12.79% |
| 2018-04-30 |
$-0.01B |
$0.09B |
-5.68% |
| 2018-01-31 |
$-0.00B |
$0.09B |
-2.25% |
| 2017-10-31 |
$-0.00B |
$0.09B |
-2.25% |
| 2017-07-31 |
$-0.00B |
$0.09B |
-2.26% |
| 2017-04-30 |
$0.03B |
$0.09B |
38.31% |
| 2017-01-31 |
$0.03B |
$0.09B |
40.13% |
| 2016-10-31 |
$0.04B |
$0.09B |
56.14% |
| 2016-07-31 |
$0.05B |
$0.09B |
73.77% |
| 2016-04-30 |
$0.02B |
$0.05B |
34.52% |
| 2016-01-31 |
$0.02B |
$0.05B |
35.96% |
| 2015-10-31 |
$0.01B |
$0.05B |
12.58% |
| 2015-07-31 |
$-0.00B |
$0.04B |
-8.11% |
| 2015-04-30 |
$-0.01B |
$0.03B |
-39.44% |
| 2015-01-31 |
$-0.01B |
$0.04B |
-30.14% |
| 2014-10-31 |
$-0.01B |
$0.04B |
-30.77% |
| 2014-07-31 |
$-0.01B |
$0.04B |
-28.57% |
| 2014-04-30 |
$-0.01B |
$0.04B |
-29.20% |
| 2014-01-31 |
$-0.02B |
$0.03B |
-47.76% |
| 2013-10-31 |
$-0.02B |
$0.03B |
-50.70% |
| 2013-07-31 |
$-0.02B |
$0.03B |
-49.03% |
| 2013-04-30 |
$-0.04B |
$0.04B |
-101.18% |
| 2013-01-31 |
$-0.04B |
$0.04B |
-75.83% |
| 2012-10-31 |
$-0.04B |
$0.05B |
-60.80% |
| 2012-07-31 |
$-0.04B |
$0.05B |
-52.96% |
| 2012-04-30 |
$-0.02B |
$0.08B |
-18.35% |
| 2012-01-31 |
$-0.01B |
$0.08B |
-16.33% |
| 2011-10-31 |
$-0.02B |
$0.08B |
-17.98% |
| 2011-07-31 |
$-0.01B |
$0.09B |
-14.05% |
| 2011-04-30 |
$-0.02B |
$0.09B |
-15.87% |
| 2011-01-31 |
$-0.02B |
$0.09B |
-18.56% |
| 2010-10-31 |
$-0.02B |
$0.10B |
-21.95% |
| 2010-07-31 |
$-0.02B |
$0.10B |
-21.90% |
| 2010-04-30 |
$-0.02B |
$0.10B |
-20.00% |
| 2010-01-31 |
$-0.02B |
$0.11B |
-18.34% |
| 2009-10-31 |
$-0.02B |
$0.12B |
-15.97% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.102B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
